Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

(2021) Hossein Borghaei et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer

(2021) Antonio Lopez-Beltran et al.   Cancers

Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase

(2021) Cristina Valero et al.   JAMA Oncology

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

(2020) N. Chaput et al.   ANNALS OF ONCOLOGY

Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling

(2020) Yaoyao Shi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma

(2020) Benjamin P. Fairfax et al.   NATURE MEDICINE

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

(2020) Robert J. Motzer et al.   CANCER

YYFZBJS ameliorates colorectal cancer progression in ApcMin/+ mice by remodeling gut microbiota and inhibiting regulatory T-cell generation

(2020) Hua Sui et al.   Cell Communication and Signaling

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

(2020) Lukas F. Mager et al.   SCIENCE

Postbiotics—A Step Beyond Pre- and Probiotics

(2020) Jakub Żółkiewicz et al.   Nutrients

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma

(2020) Igor Puzanov et al.   JAMA Oncology

Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors

(2020) Nicholas J. Salgia et al.   EUROPEAN UROLOGY

Perinatal Resveratrol Therapy Prevents Hypertension Programmed by Maternal Chronic Kidney Disease in Adult Male Offspring: Implications of the Gut Microbiome and Their Metabolites

(2020) Chien-Ning Hsu et al.   Biomedicines

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors

(2019) Arielle Elkrief et al.   OncoImmunology

The microbiome, cancer, and cancer therapy

(2019) Beth A. Helmink et al.   NATURE MEDICINE

A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

(2019) Takeshi Tanoue et al.   NATURE

Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematological malignancies carrying multidrug-resistance bacteria

(2019) Giorgia Battipaglia et al.   HAEMATOLOGICA

Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy

(2019) Agata Górska et al.   CURRENT MICROBIOLOGY

The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese non-small cell lung cancer patients

(2019) Yueping Jin et al.   Journal of Thoracic Oncology

Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus

(2019) Rebekah M. Dedrick et al.   NATURE MEDICINE

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

(2019) Yucai Wang et al.   JAMA Oncology

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

(2019) A Elkrief et al.   ANNALS OF ONCOLOGY

Gut Microbiota Shapes the Efficiency of Cancer Therapy

(2019) Weidong Ma et al.   Frontiers in Microbiology

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma

(2019) Yi Zheng et al.   Journal for ImmunoTherapy of Cancer

Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?

(2019) Romain Villéger et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision

(2019) Zeyu Chen et al.   IMMUNITY

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

(2018) L Derosa et al.   ANNALS OF ONCOLOGY

Green Tea Liquid Consumption Alters the Human Intestinal and Oral Microbiome

(2018) Xiaojie Yuan et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer

(2018) Florian Huemer et al.   Oncotarget

Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant

(2018) Ying Taur et al.   Science Translational Medicine

Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors

(2018) Jibran Ahmed et al.   OncoImmunology

Microbiota and cancer immunotherapy: in search of microbial signals

(2018) Raad Z Gharaibeh et al.   GUT

Immune Checkpoint Inhibitor Toxicity in 2018

(2018) Douglas B. Johnson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

(2018) Yinghong Wang et al.   NATURE MEDICINE

Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling

(2017) Meng Michelle Xu et al.   IMMUNITY

Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.

(2017) Lisa Derosa et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

(2017) Solange Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Bifidobacteriumcan mitigate intestinal immunopathology in the context of CTLA-4 blockade

(2017) Feng Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

The microbiome in anti-cancer therapy

(2017) Stavros Bashiardes et al.   SEMINARS IN IMMUNOLOGY

Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity

(2017) Alessandro Inno et al.   TUMORI

Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients

(2017) Arthur E. Frankel et al.   NEOPLASIA

Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity

(2017) Alessandro Inno et al.   TUMORI JOURNAL

Manipulation of the gut microbiota using resistant starch is associated with protection against colitis-associated colorectal cancer in rats

(2016) Ying Hu et al.   CARCINOGENESIS

Resetting microbiota byLactobacillus reuteriinhibits T reg deficiency–induced autoimmunity via adenosine A2Areceptors

(2016) Baokun He et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Design, Synthesis, and Biological Evaluation of Novel Cyclic Adenosine–Inosine Monophosphate (cAIMP) Analogs That Activate Stimulator of Interferon Genes (STING)

(2016) Thierry Lioux et al.   JOURNAL OF MEDICINAL CHEMISTRY

The microbiome and innate immunity

(2016) Christoph A. Thaiss et al.   NATURE

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

(2016) Krista Dubin et al.   Nature Communications

Resveratrol suppresses myofibroblast activity of human buccal mucosal fibroblasts through the epigenetic inhibition of ZEB1 expression

(2016) Yu-Chao Chang et al.   Oncotarget

Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin

(2016) Junmin Zhou et al.   Scientific Reports

STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia

(2016) Emily Curran et al.   Cell Reports

Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion

(2016) Mehrnaz Gharaee-Kermani et al.   PLoS One

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

Anti-fibrotic effect of trans-resveratrol on pancreatic stellate cells

(2015) Siu Wai Tsang et al.   BIOMEDICINE & PHARMACOTHERAPY

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria

(2015) Antony Cougnoux et al.   GUT

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment

(2014) C. Cekic et al.   CANCER RESEARCH

The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic

(2014) Colin Hill et al.   Nature Reviews Gastroenterology & Hepatology

Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation

(2013) Nicholas Arpaia et al.   NATURE

The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis

(2013) P. M. Smith et al.   SCIENCE

Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection

(2011) Ethan Gough et al.   CLINICAL INFECTIOUS DISEASES

Prebiotics and Probiotics

(2011) Eamonn M. M. Quigley   NUTRITION IN CLINICAL PRACTICE

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria

(2009) Ivaylo I. Ivanov et al.   CELL

Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function

(2008) Balázs Csóka et al.   FASEB JOURNAL